Biological & Safety Testing

Preclinical testing services

With expertise in preclinical testing services, we support the development pipeline from early discovery to candidate selection, enabling more informed decisions and reducing the risk of clinical failure.

Advanced Oncology Screening Systems

With our own published evidence and more than 30 years experience, we have optimized advanced cancer biopsy collection, cellular production and full 3D modelling in cancer. Having already partnered with oncology innovators, we have single cell, groups, cancer organoids and even 3D printed short-term and long-term screening systems that allow testing of chemotherapy combinations and dose, as well as state of the art new therapies.

Drug screening and toxicity testing services

We also offer comprehensive drug screening and toxicity testing services, helping biotech and pharmaceutical companies identify potential candidates faster while ensuring safety and efficacy.

EVQ-218 silver metamaterial

EVQ-218, our most extensively studied silver metamaterial, is backed by peer-reviewed characterization and broad-spectrum antimicrobial research. EVQ-218 is produced without added capping agents, polymers, or surfactant coatings—so the material surface remains central to its behavior. EVQ-218 has demonstrated broad-spectrum in vitro antimicrobial activity across more than 64 bacterial, fungal, and mycobacterial isolates. Published serial-passage research found no measurable increase in MIC after 30 passages across all six ESKAPE pathogens.

High-performance liquid chromatography - mass spectroscopy (HPLC-MS)

Using our Agilent Technologies HPLC-MS, we can quantify the concentration of drug in systems at any point during an experiment. Additionally, in any liver-containing HoaC system, we can determine concurrent depletion of parent compound and metabolite generation.

Drug Concentration Quantification

Know how quickly your compound is absorbed, metabolized, and excreted. Determine the precise amount of a drug at any time point out to 28 days.

Human-on-a-Chip®

Functional, multi-organ, in vitro platforms Determine therapeutic index Reducing the need for animal testing Focus is on building custom models for therapeutic development

In vivo DMPK and Pharmacokinetic Services

Our comprehensive in vivo services encompass a wide spectrum of studies to evaluate the pharmacokinetics of compounds. We conduct pharmacokinetic studies using various administration routes, including oral, intraperitoneal, intravenous, subcutaneous, and more, in a range of species, including mice, rats, rabbits, minipigs, and dogs. Our in vivo services extend to: * PK Studies: Investigating pharmacokinetics using various administration routes. * Dose Range Finding Studies: Determining the optimal dosing range for compounds. * Brain Exposure Studies: Evaluating compound penetration and distribution in the brain. Additionally, we offer specialized studies, including: * Excretion Studies: Assessing the elimination of compounds from the body. * Tissue Distribution Studies: Investigating the distribution of compounds in different tissues. * Excretion Studies: Assessing the elimination of compounds from the body. * Biliary and Urine Excretion Studies: Focusing on biliary and urinary elimination pathways. Our in vivo pharmacokinetic experts design studies that ensure translational accuracy between preclinical models and human systems, using precise bioanalytical quantification methods to deliver actionable PK insights.

Metabolite Identification

At Jubilant Biosys, we offer comprehensive metabolite identification services crucial for drug discovery and development. Metabolite identification involves detecting and characterizing the byproducts formed when a drug is metabolized in the body. Understanding these metabolites is essential for assessing a drug’s safety, efficacy, and potential toxicity. - Metabolite profiling and identification (MetlD) is the qualitative and quantitative study of the biotransformation of a drug in nonclinical animals and humans. These studies involve the structure elucidation of metabolites, assessment of the metabolic pathways along with semi-quantitative estimation of metabolites. - These studies help identify disproportionate metabolites present exclusively in human or at higher concentrations in human than in any preclinical species. safety assessment is required for such metabolites as per the MIST guidelines. - Jubilant offers comprehensive metabolite profiling services for both in-vitro and in-vivo samples. Soft spot identification: Soft spots elucidation can be performed based on compound clearance, to determine the functional groups labile to metabolism. This information will be used by the medicinal chemists for synthesis/optimization of metabolically stable compounds. In vivo met-id services - These studies involves characterization and identification of metabolites in plasma, urine, bile, and feces of the non-clinical species using multiple pooling approaches. - Integration of in vitro and in vivo met id studies enables selection of best toxicological species to predict human metabolism. Instrumentation for metabolite characterization: Thermo Q- Excotive Plus Orbitrap system with UHPLC system with UV detector - Accurate mass (less than 5 pm error) for confident biotransformation assignment and structural elucidation of metabolites. - Parallel reaction monitoring (PRM) to deliver reproducible quantitation of targeted metabolites of interest. - Semi quantitative estimation of metabolites by UV response for relatively definitive quantification.

Physicochemical Properties

Physicochemical properties refer to the physical and chemical characteristics of a substance that define its behavior in various environments and applications. These properties include aspects such as solubility, pKa and partition coefficient, among others. Such properties play a pivotal role in supporting rational compound design by providing insight into the relationship between a molecule’s structure and its physical behavior within a system. Jubilant Biosys offers comprehensive physicochemical property analysis as part of its drug discovery and development services. By utilizing advanced techniques and state-of-the-art equipment, Jubilant Biosys ensures accurate measurement and interpretation of these properties, aiding in the optimization of lead compounds. Their services include – - Distribution/Partition coefficient (Shake flask/ chromatography method). - Aqueous solubility (Thermodynamic and Kinetic). - Solubility evaluation in bio-relevant media. - Chemical stability assessment. - pKa estimation. - Early formulation assessments.

Stand Alone Pathology Services

We offer Stand Alone Pathology Services(tissue processing through slide evaluation and reporting) for the in-life phase of toxicology and efficacy studies conducted elsewhere.

Bio-Chemical Assay, D&S

The In vitro Biology Group has the expertise to perform a variety of biochemical and cellular assays against varied target classes, including enzymes, GPCR’s, NHR’s and transporters. Biochemical & cell based assay development and screening Our specialised team of scientists possesses extensive expertise in crafting and managing tailored assays, targeting a wide array of enzyme targets, non-enzymatic protein targets, RNA targets, and more. Whether procured from reputable commercial vendors or developed in-house to meet the specific needs of our clients, our seasoned scientists deliver high-quality biochemical assays and provide insightful data interpretation throughout the discovery process. We support the development and screening of a diverse range of scalable biochemical assays, including label-free detection, absorbance, fluorescence, luminescence, and HTRF technologies, as well as binding assays. All of these are conducted utilizing industry-standard instrumentation platforms across various target classes. We have worked on: - Kinases - Other non-Kinase Enzymes - GPCRs and Ion channels - Transcription factors - Immune regulators - Degraders

Surface Plasmon Resonance (SPR) Services

Biophysical Facility at Jubilant Biosys provides highly sensitive, label-free and real-time assessment of biomolecular interaction through the Surface Plasmon Resonance (SPR) technology/platform. Our SPR services are carried out by our experienced scientific team that guides you through your project for various applications ranging from small molecule binding kinetics (reversible/irreversible), fragments screening, protein aggregation, drug competition assay etc. With extensive knowledge in the drug discovery process, Jubilant Biosys offers tailored SPR solutions to complex challenges, supporting small molecules and biologics, including antibody drug conjugate programs, to help deliver successful results and achieve our mission. An optical phenomenon, SPR, enables binding activity monitoring of any two unlabelled molecules in real-time. The generated signal is dependent on changes in the refractive index at the surface of a gold sensor chip, as an analyte flows in a microfluidic channel and binds to a ligand immobilized on the sensor chip. Consequently, over time, plotting the binding response vs time called sensorgram. The sensorgram aids in the calculation of binding parameters, such as K D, k on and k off. Advantages of SPR Technology - Deeper insight and understanding of molecular interactions – Real-time monitoring. - Small sample sizes. - Replicate measurements consistently. - Label-free detection. - Reusable sensor chips. Analysis for which the SPR services can be applied for On top of the kinetic constants, SPR measurements can be applied for: - Determination of affinity. - High Throughput Screening of Fragments. - Assessment of irreversible compounds. - Competition assay.

In vitro Biology & Pharmacology Solutions

The In vitro Biology Group has the expertise to perform a variety of biochemical and cellular assays against varied target classes, including enzymes, GPCR’s, NHR’s and transporters. Our facility is equipped with necessary infrastructure and updated technologies for in vitro pharmacology services to enable these undertakings, supported by liquid-handlers, compound-managers and multi-mode detection systems. With a high ratio of PhD scientists with global exposure and long-standing discovery experience, Jubilant Biosys is well-placed to support target validation, assay development, screening and mechanism of action for first-in-class & best-in-class requirements. The following functional services are provided: - Biochemical based assay development, validation & screening. - Biophysical assay development, validation & screening. - Cell-based assay development, validation & screening. - Immune-cell based development, validation & screening. Assay Technologies: - Absorbance. - Fluorescence – FP, TR-FRET, HTRF, Lance. - Luminescence and alpha technology. - ELISA, FACS. - Traditional, JESS, LYCOR. - FLIPR Penta. - Radiometric – SPA, Filter Binding, Flash Plate. - Label free approaches. Our experienced team of in vitro pharmacology brings strong problem-solving skills and expertise in a large variety of assays involving platforms mentioned above. Biology Assay Development & Validation: Our biologists assist with appropriate and aminable assays to screen small molecules and support discovery from hit-to-lead, lead to optimization to preclinical candidate. Our expertise lies in various therapeutic areas, including oncology, CNS, metabolic disorders, pain & inflammation. We have successfully delivered over 100 IDD programs including first-in-class and best-in-class requirements for leading pharma & biotech companies.

Repeated Dose Toxicity Studies in Rodents and Non-Rodents

Sub-acute Toxicity: 14 days DRF and 28 days with toxicokinetic studies (OECD 407, -ICH Harmonised Tripartite Guideline – S3A: Toxicokinetics, ICH M3 (R2)). Sub-chronic Toxicity: 90 days with toxicokinetic studies (OECD 408, ICH Harmonised Tripartite Guideline – S3A, ICH M3 (R2)). Standalone Toxicokinetic studies (ICH Harmonised Tripartite Guideline – S3A: Toxicokinetics).

Pain and Neuroscience Animal Models

Neuropathic Pain Models: CCI/SNI/PSNL models (rats & mice); SNL model (rats); Formalin induced nociception; Capsaicin induced nociception. Disease Specific Pain Models: Chemotherapy induced mechanical allodynia; Bone cancer pain model; Streptozotocin induced diabetic neuropathy. Inflammatory Pain Models: CFA induced mechanical hyperalgesia; Dexamethasone induced muscle atrophy in mice; Isolation of various brain regions using brain matrices; Experience in target validation and development of target engagement models. Alzheimer’s Disease / neurodegeneration Models: MOG-EAE model of multiple sclerosis in rats and mice; Intrathecal / stereotaxic surgeries to inject compounds in different parts of spinal cord and brain; Collection of CSF in rats; PK-PD Correlations using free tissue and brain concentrations.

In-vitro Toxicology Services

Bacterial Reverse Mutation Test (Ames Test) using Salmonella Typhimurium and E.coli WP2 uvr A. In-vitro Mammalian Chromosome Aberration Test using Human Peripheral Blood Lymphocytes. In-vitro micronucleus test using Human Peripheral Blood Lymphocytes.

Drug Interactions

At Jubilant Biosys, we provide a comprehensive drug interaction assessment service as part of our integrated DMPK services, essential for scientific research and drug development. Drug interactions occur when one drug affects the activity of another when both are administered together, potentially leading to reduced efficacy or increased toxicity. This proactive approach is vital for minimizing adverse effects and optimizing drug formulations. Our service enhances the efficiency of drug development, reduces the risk of costly late-stage failures, and accelerates time-to-market for new pharmaceuticals. By leveraging our drug interaction checking service, scientists can ensure safer, more effective drug profiles, reinforcing Jubilant Biosys’s commitment to innovation and excellence in the life sciences. We offer our clients an expansive portfolio of DDI services to mitigate this risks in new drugs. These services include various assays for perpetrator and victim DDI assessment - Reversible Cytochrome P450 (CYP) Inhibition – IC50 and Ki - Time Dependent Inhibition CYP Inhibition – IC50 shift - UGT Inhibition – IC50 andKi - CYP Reaction Phenotyping - CytochromeP450 Induction through catalytic activity - Primary hepatocytes (CYP1A2, 2B6, 3A4) - PXR Nuclear Receptor Activation in HepG2 cells (single point, EC50/Emax) - Transporter Inhibition (Efflux and Uptake) –Single point/ IC50 determination - OATP1B1/1B3 - MATE1/2-K - OAT1/3 - OCT2 - Transporter Substrate Identification (Efflux and Uptake) - PgP - BCRP

Biomarker Evaluation

A high-quality, sensitive biomarker can provide crucial insights to project teams throughout the program and development continuum, guiding strategic decisions as projects move towards clinical application. Biomarker Discovery and Identification Jubilant Biosys employs a collaborative and adaptable approach to biomarker discovery and validation, ensuring the development of a suitable and robust biomarker tailored to specific objectives. Our extensive expertise includes the identification and validation of pharmacodynamic (PD) biomarkers such as pathway markers, phosphoproteins, and cytokines. Biomarker Analysis The ability to measure relevant biomarkers with precision and sensitivity is crucial for making critical go/no-go study decisions. Leveraging years of experience in sample processing and assay design, Jubilant Biosys supports pathway-relevant biomarker analysis in discovery programs. We offer analysis via qPCR, traditional Western/JESS, FACS, and other readouts.

In vitro DMPK Services

Our team specializes in providing end-to-end in vitro ADME services, covering all key areas—absorption, distribution, metabolism, and excretion. With a wealth of experience, we provide expert guidance throughout the drug discovery journey, spanning from the initial hit identification phase to lead optimization, and ultimately culminating in the identification of clinical candidates. Our in-depth in vitro ADME services are designed to provide valuable insights and data that help address potential issues and enhance the efficiency of your drug development endeavors. Key areas of expertise within our In Vitro ADME services include: Physiochemical Studies: * Kinetic solubility assessments. * Chemical stability evaluations. * Thermodynamic solubility in PBS, SGF, SIF. * Early formulation assessments, and more. In Vitro Metabolism Services: * Metabolite stability studies using liver microsomes, hepatocytes, rCYPs, and S-9 fractions. * Blood/plasma/brain/tissue/microsomal protein binding studies. * CYP phenotyping and CYP induction using PXR cell lines. * GSH (Glutathione) adduct evaluations. In Vitro Permeability and Transporter Studies: * MDCK/Caco-2 permeability assessments. * CYP profiling to understand the involvement of CYP enzymes. * TDI (Therapeutic Dose Index), and more. * Inhibition and substrate evaluations of P-glycoprotein (P-gp) and BCRP (Breast Cancer Resistance Protein) transporters. * CYP (Cytochrome P450) inhibition studies. * Stability assessments in plasma, buffer, blood, and blood/plasma ratio. * PAMPA (Parallel Artificial Membrane Permeability Assay) studies. Our in vitro DMPK scientists deliver high-throughput, reproducible data that help streamline candidate prioritization and predict human pharmacokinetics early in the pipeline.

In Vitro ADME

In Vitro Drug Metabolism and Pharmacokinetics (DMPK) studies are crucial in the early stages of drug discovery and development. These studies provide vital information about the metabolic stability, enzyme inhibition, and potential drug-drug interactions of new chemical entities. By assessing these parameters in vitro, researchers can predict the behavior of drugs in vivo, thereby optimizing their pharmacokinetic profiles and enhancing their chances of success in clinical trials. Key In Vitro DMPK Services: - Metabolic Stability: Assessing the rate at which a drug is metabolized in liver microsomes, hepatocytes, and other biological matrices. - Enzyme Inhibition: Evaluating the potential of a compound to inhibit key drug-metabolizing enzymes such as CYP450s. - Enzyme Induction: Determining if a compound induces the production of drug-metabolizing enzymes, affecting the metabolism of other drugs. - Drug-Drug Interaction Studies: Predicting potential interactions with other medications that may be co-administered. - Permeability and Transporter Studies: Evaluating how well a drug is absorbed and identifying the involvement of specific transporters. Jubilant’s DMPK services are designed to support drug discovery and development programs by providing comprehensive in vitro DMPK studies. Here’s how Jubilant can assist: - State-of-the-Art Facilities: Jubilant boasts advanced laboratories equipped with cutting-edge technology to conduct high-quality DMPK studies. - Experienced Team: Our team of experts, with extensive experience in drug metabolism and pharmacokinetics, ensures that your compounds are thoroughly evaluated and characterized. - Customized Solutions: We offer tailored services to meet the specific needs of your drug development program, providing you with relevant and actionable data. - IVIVE: Jubilant integrates in vitro ADME data with in vivo pharmacokinetics to establish In vitro in vivo extrapolation. Also, integrates with in vivo pharmacology, toxicology, Metabolite characterization in multiple species and helps in comprehensive understanding of your compound’s behavior. - Timely Delivery: We understand the importance of timely data in drug development. Our streamlined processes ensure that you receive accurate and reliable results promptly. Partner with Jubilant for your in vitro DMPK needs and leverage our expertise to enhance the pharmacokinetic profiles of your drug candidates, accelerating their progress through the development pipeline.

Cell Based Assay, D&S

The In vitro Biology Group has the expertise to perform a variety of biochemical and cellular assays against varied target classes, including enzymes, GPCR’s, NHR’s and transporters. Creating resilient and relevant In Vitro cell-based assay solutions is essential for maximising the potential success of your drug discovery projects. Our team of biologists excel at providing precisely tailored cellular assays and offers continuous support in interpreting results. Tailored Cell Assays: With experienced cell biologists at the helm, we develop a diverse array of cell-based assays to support your drug discovery research program. Our bioscience specialists appreciate the unique nature of each project and the necessity of designing robust screening cascades to guide and advance project progression. Our scientists, pathways and therapeutic areas experts, work closely with your project team to offer intellectual input in designing flexible and reliable assay solutions. These assays are crucial for fully characterizing the potency and selectivity of medicinal chemistry submissions. Our scalable assay development methods can adapt to evolving project requirements. Enhancing Compound Profiling with Specialized Screening Cascades: Partnering with Jubilant Biosys enables the creation of fully integrated and clearly defined screening cascades, simplifying compound profiling to help you make more informed decisions about compound progression. This approach accelerates the journey towards identifying a pre-clinical candidate. We provide a wide range of biophysical, biochemical, cell-based, immunologic and translational assays, all customized and optimized to meet your specific needs. The variety of assay platforms allows for the comprehensive assessment of your novel molecules for potency, efficacy, kinetics, mechanism of action, selectivity, and more, all within the most physiologically relevant context possible.

Oncology Animal Models

Xenograft Solid Tumor Models: Pancreatic cancer (MiaPaCa2, PANC1 & BxPC3); Lung cancer (A549); Gastric cancer (SNU-5 & Hs746T); Colon cancer (HCT116, Colo 205, SW620, DLD-1 & LoVo); Prostate cancer (PC3, 22RV1 & DU145); Ovarian cancer (OVCAR3); Breast cancer (MCF7); Melanoma cancer (A375). Xenograft Liquid Tumor Models: Acute Myeloid Leukemia (KG-1); Chronic Myeloid Leukemia (K-562); Erythroleukemia (HEL 92.1.7). Orthotopic Xenograft Models: Glioblastoma (U87-MG). Subcutaneous Syngeneic Models: Colon Cancer (CT26); Melanoma Cancer (B16F10); Breast Cancer (4T1, EMT6); Kidney Cancer (Renca); Lung Cancer (KLN205 & LL/2 (LLC1)); Pancreatic Cancer (LTPA). Orthotopic Syngenic Tumor Model: Breast Cancer (4T1, EMT6); Kidney Cancer (Renca). Luciferase cell lines: A total of 27 cell lines are available with Luc tagging for IVIS based xenograft models.

Novel Therapeutic Modalities

* PROTACs & Molecular Glues: Permeability, efflux profiling, ternary complex studies, linker stability, LC PRM MS characterization * Oligonucleotides: UV260/LC MS quantitation, n 1/n x metabolite mapping, biodistribution, Endosomal escape studies * ADCs: total antibody and free payload PK (HRMS/ELISA), conjugate ELISA quantification, linker stability, and catabolite mapping. * Peptides & Macrocycles: protease susceptibility, PAMPA peptide, HRMS confirmation * mRNA/LNP: particle size, lipid excipient profiling, biodistribution

Acute Studies

Single dose toxicology studies in rodents (rats/mice). Single extended dose toxicity studies in rodents (rats/mice). Single dose toxicology studies in non-rodents (rabbits).

In Vivo Pharmacokinetics

Our in vivo pharmacokinetics services include dose administration, sample collection, bioanalytical analysis, and data interpretation. We are committed to delivering high-quality data with fast turnaround times, enabling our clients to make informed decisions quickly and efficiently. We prioritize compliance with regulatory guidelines and ethical standards, ensuring that our pharmacokinetic studies advance your drug development projects and also uphold the highest standards of research integrity. Partner with us to leverage our expertise and accelerate your path to clinical success. - At Jubilant Biosys, we offer comprehensive DMPK services, including support for non-GLP in vivo pharmacokinetics studies in preclinical rodent species, encompassing study planning and sample analysis using state-of-the-art UPLC-MS/MS (Q-trap, triple quad). - We offer administration routes and collection methods include dosing by oral (PO), intravenous (IV), intraperitoneal (IP), and subcutaneous (SC) as single agents or cassette dosing (up to 6 in 1) - Capability to develop fit for purpose ADME and in vivo pharmacokinetic studies to scientifically support client requirements - Jubilant Biosys is deeply committed to upholding the principles of the 3Rs – Replacement, Reduction, and Refinement – in all our scientific endeavours. PK services offered by Jubilant Rodents and non-rodents - Rats (multiple strains) - Mouse (multiple strains) - Beagle dogs - Monkeys (Rhesus) - Mini-pigs - Rabbits - Dose proportionality studies - Biliary, Urinary, fecal excretion studies Tissue distribution studies in rodents - Exposure kinetics in tissues of choice - Cerebrospinal fluid collection - BALF fluid collection Dermal pharmacokinetics in rodents and non rodents Mechanistic pharmacokinetics models in rats - Bile duct cannulation - Portal vein cannulation - Carotid artery cannulation - Jugular vein cannulation - Femoral vein cannulation - Expertise in developing quantitative LC-MS/MS methods for endogenous biomarkers in bio-fluids and tissue samples

Mode of Action Studies

The In vitro Biology Group has the expertise to perform a variety of biochemical and cellular assays against varied target classes, including enzymes, GPCR’s, NHR’s and transporters. Comprehending Mechanism of Action (MOA): Approaches, Techniques, and Characterization Unraveling the mechanism of action through which a compound modulates its target’s function or the biology of cells is paramount to establishing the target engagement and target mediated outcome. Jubilant Biosys excels in employing various complementary approaches to identify a compound’s mechanism of action. Classical enzymology techniques are utilized to discern whether compounds belong to the four main classes of activity inhibition: competitive, non-competitive, mixed, and uncompetitive. Additionally, reversibility can be established by multiple methods and tailored evaluation. Understanding Compound Mechanism of Action To determine a compound’s mechanism of action on receptor targets, classical pharmacology experiments are used to characterize receptor agonists and antagonists, while biophysical methods are employed to characterize binding kinetics and competition with other non-enzyme targets. For a deeper understanding of a compound’s molecular MOA, structural approaches help elucidate target engagement and also establish the precise interaction Jubilant Biosys utilizes protein production and crystallography to characterize compound binding at a structural level. Our scientists have a comprehensive set of skills and techniques that enable thorough characterization of the mechanism of action: - Exhaustive characterization of mechanism action is achievable through classical enzymology methods. - Tight binding and reversibility are discerned through kinetic and biophysical methods. - Competitive Biophysical assays enable characterization of compound MOA across a full spectrum of targets. - A comprehensive understanding of the compound binding site is attained through structural biology. - Pathway Evaluation to understand distinct mode of action.

In-vivo Pharmacology & Biology Services

Elevate your research to new heights and uncover groundbreaking discoveries in the realm of In-Vivo Biology which is the nexus of cutting-edge scientific exploration, renowned for its exceptional features that drive innovation and discovery. With a seasoned team of expert researchers and scientists at its core, the department offers unmatched expertise in the field of in-vivo biology. These experts collaborate seamlessly with researchers across various disciplines, providing tailored solutions to meet unique research objectives. A diverse array of in-vivo models, from mice to rabbits, coupled with myriad of downstream biomarker estimations enables comprehensive investigations into an extensive range of biological phenomena. The department boasts a state-of-the-art infrastructure, including advanced technologies and tools, ensuring researchers have access to the latest innovations. Ethical standards are paramount, with a deep commitment to the humane treatment and welfare of research animals. This dedication, combined with efficient workflows and data analysis capabilities, ensures timely and impactful results.

Large Molecule Bioanalysis

Technology platforms: First-class triple quadrupole and high-resolution MS systems: - SCIEX Triple Quad TM '4000/4500/5500/6500 - SCIEX Q-Trap TM 4000 - Thermo Scientific TM Q Exactive TM Plus UPLC systems - Waters ACQUITY TM UPLC TM - Waters ACQUITY TM UPLC TM I-Class PLUS Agilent G95318 Rapid fire 365 high throughput system hyphenated with Triple Quad (MultiQuant software) Automated liquid handling platforms - Biomek systems

Inflammation Animal Models

Fibrosis Models: Lung fibrosis in mice (LPS/Bleomycin); Liver fibrosis in mice (CCl4). Kidney Models: Unilateral Ureteral Obstruction (UUO) in mice; Adenine diet induced Kidney Injury in mice; 5/6 Nephrectomized Animal Model. Wound Healing: Diabetic Wound Healing in mice. Inflammatory Bowel Disease Models: DSS & Oxazolone-induced Ulcerative Colitis in mice; TNBS-induced Colitis in rats (acute). Systemic Lupus Erythematosus (SLE) Model: MRL/lpr. Arthritis Model: Collagen induced arthritis (CIA); Collagen Antibody Induced Arthritis (CAIA). Skin Models: TPA induced contact dermatitis; Oxazolone induced allergic contact dermatitis; Imiquimod induced psoriasis in mice and rats; IL23 induced acanthosis in mice and rats.

Diabetes & Metabolic Disorders Animal Models

Glucose tolerance test in rat and mice: Oral; Intraperitoneal; Intravenous. Pyruvate tolerance test. Insulin tolerance Test. Genetic disease models of diabetes: ZDF rats; ob/ob mice; db/db mice. DIO models: Rat; Mice; nSTZ-HFD fed NASH mice model; CDA-HFD NASH model; NAFLD mouse model; STZ induced diabetic model in mice and rats; STZ induced diabetic nephropathy in mice and rats; GI emptying model in mice.

Biophysical Analysis Services

'- Dye-based Thermal shift assay. - Protein’s melting temperature measurement (Tm). - Identification of suitable protein storage buffer. - Assessment of ligand binding. - Mass spectrometry(DMPK). - Intact mass measurement. Protein identity and post-translational modifications. - Surface plasmon resonance. - Sartorius FE system in place. k on, k off& KD in a single injection. Evaluation of irreversible inhibition by k inact/Kl or k on. Fragment Screening of low MW fragments (~125Da).

Whole Cell Proteomics

Evaluation of global proteome induced changes by PROTACs and small molecule drugs establishes efficacy and specificity of drug molecules.

DUB Assays, Screening & Profiling

Deubiquitylases (DUBs) are enzymes that can reverse the effect of E3 ligases by removing the ubiquitin from the target proteins. Unlike most E3 ligases, DUBs have inherent catalytic activity that is easily targeted by small molecules.

Tissue Analysis via TUBE-based Mass Spec

Using abundance measurements with ubiquitination data, mass spectrometry provides a systems-level view of how disease perturbs protein homeostasis. Mass spectrometry–based proteomics is especially important for studying disease because it allows direct measurement of protein abundance changes while also capturing regulatory mechanisms that cannot be inferred from gene or mRNA data alone. In many diseases, proteins are up- or down-regulated not because of altered transcription, but because of changes in stability and turnover. Since proteins are the functional molecules that execute cellular processes, observing their actual levels provides a more accurate picture of disease biology than genomics or transcriptomics alone. Ubiquitination plays a central role in controlling protein degradation, signaling, and cellular quality control, and its dysregulation is a hallmark of many diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. Mass spectrometry proteomics enables the identification and quantification of ubiquitinated proteins and specific ubiquitination sites, allowing researchers to see which proteins are being selectively targeted for degradation or altered signaling. This is critical for understanding disease mechanisms where abnormal protein accumulation or excessive protein loss drives pathology, such as the buildup of misfolded proteins in neurodegeneration or the enhanced degradation of tumor suppressors in cancer. By integrating protein abundance measurements with ubiquitination data, mass spectrometry provides a systems-level view of how disease perturbs protein homeostasis. Researchers can distinguish whether changes in protein levels arise from altered synthesis or from ubiquitin-mediated degradation, and they can map entire pathways affected by disrupted ubiquitin signaling. This makes mass spec proteomics a powerful tool for identifying disease biomarkers, uncovering therapeutic targets within the ubiquitin–proteasome system, and evaluating how drugs modulate protein stability and turnover in disease contexts. LifeSensors’s TUBEs offers the most natural way of studying ubiquitination without modifying the target, or the ubiquitin chain, especially important for avoiding artifacts in such a valuable research tool.

Proteomics of Induced Proximity-Based Degraders

PROTACs®/Molecular Glues/Ubiquitination Modifiers Mass spectrometry is a critical tool for evaluating PROTACs and molecular glues because it directly measures endogenous protein degradation and the ubiquitin-mediated mechanisms that drive targeted protein degradation (TPD). Proteomics can quantify changes in target protein abundance, confirm engagement of the ubiquitin–proteasome system through detection of ubiquitinated peptides, and distinguish true degradation from indirect effects. This direct readout is especially important for event-driven pharmacology, where transient compound binding leads to sustained protein loss. Beyond confirming target knockdown, mass spectrometry provides a system-wide view of degrader selectivity and mechanism. Proteome-wide analyses can reveal off-target degradation, neo-substrates induced by molecular glues, and pathway-level consequences that are not predictable from binding or reporter assays. Time-resolved MS experiments further help dissect the sequence of ubiquitination and protein clearance, supporting rational optimization of degrader potency and specificity. Luciferase-based assays remain valuable for early screening due to their speed and sensitivity, but they rely on engineered reporter systems that may not reflect endogenous regulation. Changes in reporter signal can arise from transcriptional effects, cytotoxicity, or reporter instability rather than true protein degradation. In contrast, mass spectrometry provides unambiguous, physiologically relevant evidence of target degradation and selectivity, making it the gold standard for mechanistic validation of PROTACs and molecular glues. TUBE based pulldown, evaluation and reporting allows LifeSensors to offer a top of the line service to evaluate the impact of PROTACs and Molecular Glues.

HTS TR-FRET Alexa TUBEs

LifeSensors offers a range of powerful assays that can be run in-house, from gel and TR-FRET assays, to auto-ubiquitination and substrate ubiquitination assays

Substrate ID: DUBs

The Ubiquitin Proteasome System (UPS) controls the principal functions of almost all the cellular proteins of human cells and failures in this system often contribute directly or indirectly to the pathogenesis of many diseases, including cancer, inflammation, and neurodegeneration. There are ~100 deubiquitinases (DUBs) encoded in human genome and the functions of most of these DUBs remain unknown. Identification of substrates of individual DUBs is an essential step to unravel the cellular functions of DUBs. Not only limited to DUBs, but there are also ~700 E3 ubiquitin ligases encoded in human genome and the functions of most of these E3s remain unknown. Recent development of PROTAC drugs to recruit E3 ligases and degrade therapeutic proteins highlight the value of studying E3 ligases. Substrate identification in individual E3 ligases is an essential step to unraveling cellular functions of E3s and identifying novel therapeutic targets. LifeSensors can help you identify the substrates of your preferred E3s and DUBs. Advantages of Choosing LifeSensors For Your Drug Discovery Project In Vitro & In Cell Assays Comprehensive assays to identify DUB & E3 substrates in controlled environments and cellular contexts TUBEs for Detection Advanced TUBE technology enables identification of direct deubiquitination targets Substrate Trapping & Proteomics State-of-the-art proteomic analysis to identify endogenous substrates with precision Orthogonal Validation Rigorous validation of substrates through independent orthogonal assay methods

E3 Ubiquitin Ligases Profiling & Screening

At LifeSensors, we have developed reagents and assays encompassing both traditional and non-traditional approaches for E3 ligase screening and profiling. LifeSensors’ small molecule library contains a collection of ligase-centric compounds, which can be employed as a gold standard for your ligase drug discovery efforts.

Gel-Based Assays

Gel-based ubiquitination assays provide direct, confirmation of ubiquitination and ligase activity, valuable for mechanistic validation in E3 ligase, PROTAC, and molecular glue studies.